- Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer2020 | Lékařská fakulta v Hradci Králové
- Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression2016 | Lékařská fakulta v Hradci Králové
- Extracorporeal elimination of circulating pegylated liposomal doxorubicin (PLD) to enhance the benefit of cytostatic therapy in platinum-resistant ovarian cancer patients2015 | Lékařská fakulta v Hradci Králové
- Výzkumná zpráva Fakultní nemocnice ke klinickému hodnocení EC-FV-06Publikace bez příslušnosti k fakultě
- Liposomal Doxorubicin Combined with Regional Hyperthermia: reducing Systemic Toxicity and Improving Locoregional Efficacy in the treatment of Solid Tumors2004 | Lékařská fakulta v Hradci Králové
- Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma2016 | 1. lékařská fakulta
- Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years2020 | Lékařská fakulta v Hradci Králové
- Extracorporeal apheresis system - A nanoparticle drugs' elimination method to enhance the benefit of cytostatic therapy in cancer patients2016 | Lékařská fakulta v Hradci Králové
- Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression2007 | 1. lékařská fakulta
- Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)2019 | 3. lékařská fakulta